iX Biopharma (SGX:42C) Debt-to-Equity : 1.40 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Debt-to-Equity?

iX Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was S$2.95 Mil. iX Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was S$1.97 Mil. iX Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was S$3.51 Mil. iX Biopharma's debt to equity for the quarter that ended in Dec. 2024 was 1.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for iX Biopharma's Debt-to-Equity or its related term are showing as below:

SGX:42C' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.22 Max: 1.4
Current: 1.4

During the past 11 years, the highest Debt-to-Equity Ratio of iX Biopharma was 1.40. The lowest was 0.01. And the median was 0.22.

SGX:42C's Debt-to-Equity is ranked worse than
91.52% of 814 companies
in the Drug Manufacturers industry
Industry Median: 0.26 vs SGX:42C: 1.40

iX Biopharma Debt-to-Equity Historical Data

The historical data trend for iX Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Debt-to-Equity Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.39

0.36

0.22

0.27

1.20

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.22	0.27	0.79	1.20	1.40

Competitive Comparison of iX Biopharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

iX Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

iX Biopharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.877	+	2.324)	/	4.34
	=	1.20

iX Biopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.954	+	1.969)	/	3.514
	=	1.40

iX Biopharma (SGX:42C) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

iX Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines